Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

As India grapples with a mounting obesity crisis — with over 250 million individuals affected and health costs projected to ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

Danish pharmaceutical company Novo Nordisk plans to introduce its weight-loss drug Wegovy in India earlier than planned to ...

Novo Nordisk will invest $1.09 billion in Brazil to enhance production of injectable drugs for obesity and diabetes. This ...

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...